LB-100 tosylate 2016 Jan 20:ajpcell

2016 Jan 20:ajpcell

Smiles: CC(C)(C(=O)N[C@H]1C2=CC=CC=C2C2=CC=CC=C2NC1=O)C(=O)NCC(F)(F)C(F)(F)F

Currently it is in Phase II/III clinical trials for Hodgkin's lymphoma and advanced breast cancer

CAS Number: 1450644-28-6

LB-100 tosylate 2016 Jan 20:ajpcellLB 100 is a protein phosphatase 2A(PP2A)inhibitor. LB 100 sensitizes hepatocellular carcinoma cells to the effects of sorafenib during hypoxia by activation of Smad3 phosphorylation. LB 100 enhanced the effects of sorafenib in HCC cells only during hypoxic environments. LB 100 dramatically increased intracellular p Smad3 level, which was responsible for the effect of LB 100 as a sensitizer. LB 100 downregulated Bcl 2 expression and enhanced sorafenib